Publications by authors named "U Jaschinski"
Background: ICU nurses are most frequently at the patient's bedside, providing care for both patients and family members. They perform an essential role and are involved in decision-making. Despite this, research suggests that nurses have a limited role in the end-of-life decision-making process and are occasionally not involved.
View Article and Find Full Text PDFArticle Synopsis
- Researchers wanted to know if hospital data on sepsis (a serious infection) was correct enough to help make decisions about healthcare.
- They checked records from 10,334 patients in 10 hospitals in Germany to see if the doctors correctly mentioned sepsis in their notes.
- They found that sometimes sepsis was missed or not written down, which means earlier reports of how many people had sepsis were too low, and hospitals varied a lot in how well they identified it.
End-of-life practices in 11 German intensive care units : Results from the ETHICUS-2 study.
Med Klin Intensivmed Notfmed
November 2023
Background: End-of-life care is common in German intensive care units (ICUs) but little is known about daily practice.
Objectives: To study the practice of end-of-life care.
Methods: Prospectively planned, secondary analysis comprising the German subset of the worldwide Ethicus‑2 Study (2015-2016) including consecutive ICU patients with limitation of life-sustaining therapy or who died.
Purpose: To investigate whether (1 → 3)-β-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive Candida infection (ICI).
Methods: Multicenter, randomized, controlled trial carried out between September 2016 and September 2019 in 18 intensive care units enrolling adult sepsis patients at high risk for ICI. Patients in the control group received targeted antifungal therapy driven by culture results.
Unlabelled: Anaphylatoxin C5a, a proinflammatory complement split product, plays a central role in mediating organ dysfunction.
Objectives: This phase II clinical trial was conducted to study safety, tolerability, pharmacokinetics, and pharmacodynamics of vilobelimab, a recombinant monoclonal antibody against C5a, in patients with severe sepsis or septic shock.
Design: Multicenter, randomized, and placebo-controlled study.